1431839-31-4Relevant articles and documents
Pyridazine Derivatives Useful in Therapy
-
Page/Page column 34-35, (2013/05/21)
The invention provides compounds of formula I, (I) wherein: R represents a cyclic group selected from phenyl, heteroaryl,heterocyclyl and C 3-6 cycloalkyl;10 wherein each cyclic group is optionally substituted with from 1 to 3 substituents selected from halo, C -6 alkyloptionally substituted with 1-3 halogen atoms, phenyl, C -6 alkoxy optionally substituted with 1-3 halogen atoms, cyano, heteroaryl 1a andheterocyclyl 1a; and wherein each cyclic group is optionally fused to a benzene ring or a 5-or 1 6-membered heteroaromaticor heterocyclic ring each containing from 1 to 3 heteroatoms (selected from N, O and S); and when the group is substituted the substitution may occur anywhere on the optionally fused ring system as a whole; and wherein heterocyclyl and heterocyclyl 1a may additionally be substituted with =O;20 X represents a bond or C -6 alkylene (which may be straight or branched); R 2 represents H or C -6 alkyl; R 3 represents H or C -6 alkyl; Y represents a bond or C -6 alkylene (which may be straight or branched, and optionally substituted with OH or CF 3 );2 R 4 represents a cyclic group selected from phenyl, heteroaryl 4,heterocyclyl 4 and C 3-6 cycloalkyl; wherein each cyclic group is optionally substituted with from 1 to 3 substituents selected from halo, C -6 alkyloptionally substituted with 1-3 halogen atoms, TET01063WO 4 phenyl,C -6 alkylsubstituted with phenyl,C -6 alkoxy optionally substituted with -3 halogen atoms, cyano, heteroaryl 4a andheterocyclyl 4a; and wherein each cyclic group is optionally fused to benzene ring or a 5-or 6-membered heteroaromaticor heterocyclic ring each containing from 1 to 3 heteroatoms (selected from N, O and S); and when the group is substituted the substitution may occur anywhere on the optionally fused ring system as a whole; and wherein heterocyclyl 4 and heterocyclyl 4a may additionally be substituted with =O; heteroaryl, heteroaryl 1a, heteroaryl 4 and heteroaryl 4a independently represent a 5-or 6-membered heteroaryl group containing from 1 to 3 heteroatoms (selected from N, O and 10 S); and heterocyclyl, heterocyclyl 1a, heterocyclyl 4 and heterocyclyl 4a independently represent a 5- or 6-membered heterocyclyl group containing from 1 to 3 heteroatoms (selected from N, O and S); and pharmaceutically acceptable salts and solvates thereof.1 The compounds are useful as pharmaceuticals, particularly in the treatment of fibrotic diseases, cancer and pain.
